Nathan J. Dowden's most recent trade in Entrada Therapeutics Inc was a trade of 90,800 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 90,800 | 90,800 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 60,800 | 185,949 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.68 per share. | 01 Mar 2025 | 5,144 | 180,805 | - | 11.7 | 60,075 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 26 Sep 2024 | 847 | 125,149 | - | 16 | 13,552 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 06 Sep 2024 | 1,904 | 125,996 | - | 15.1 | 28,690 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Sale of securities on an exchange or to another person at price $ 15.20 per share. | 06 Sep 2024 | 399 | 127,900 | - | 15.2 | 6,063 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.42 per share. | 03 Sep 2024 | 983 | 128,470 | - | 15.4 | 15,161 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.76 per share. | 03 Sep 2024 | 483 | 129,624 | - | 15.8 | 7,613 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.13 per share. | 03 Sep 2024 | 171 | 128,299 | - | 15.1 | 2,587 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.92 per share. | 03 Sep 2024 | 156 | 129,468 | - | 16.9 | 2,640 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.73 per share. | 03 Sep 2024 | 15 | 129,453 | - | 17.7 | 266 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Sale of securities on an exchange or to another person at price $ 16.26 per share. | 16 Aug 2024 | 26,595 | 130,609 | - | 16.3 | 432,419 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.74 per share. | 16 Aug 2024 | 20,000 | 157,204 | - | 1.7 | 34,800 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Aug 2024 | 20,000 | 64,831 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Sale of securities on an exchange or to another person at price $ 16.70 per share. | 16 Aug 2024 | 502 | 130,107 | - | 16.7 | 8,382 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Sale of securities on an exchange or to another person at price $ 12.32 per share. | 06 Mar 2024 | 1,826 | 137,204 | - | 12.3 | 22,499 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 60,000 | 141,268 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 50,100 | 50,100 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 33,100 | 81,268 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.28 per share. | 01 Mar 2024 | 1,486 | 139,030 | - | 12.3 | 18,246 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.37 per share. | 01 Mar 2024 | 409 | 140,516 | - | 13.4 | 5,467 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.42 per share. | 01 Mar 2024 | 343 | 140,925 | - | 12.4 | 4,261 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 10 Jul 2023 | 3,897 | 35,376 | - | 18.0 | 70,333 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.00 per share. | 10 Jul 2023 | 3,200 | 39,273 | - | 18.0 | 57,605 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 14.94 per share. | 20 Jun 2023 | 8,885 | 49,570 | - | 14.9 | 132,704 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 20 Jun 2023 | 7,097 | 42,473 | - | 16.0 | 113,700 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 21,500 | 21,500 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 14,200 | 58,455 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 24.05 per share. | 31 Oct 2022 | 2,100 | 45,283 | - | 24.0 | 50,495 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.97 per share. | 25 Oct 2022 | 5,414 | 48,283 | - | 21.0 | 113,526 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 20.10 per share. | 25 Oct 2022 | 3,034 | 53,697 | - | 20.1 | 60,996 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 21.85 per share. | 25 Oct 2022 | 900 | 47,383 | - | 21.9 | 19,669 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.29 per share. | 20 Oct 2022 | 2,771 | 59,135 | - | 18.3 | 50,668 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.66 per share. | 20 Oct 2022 | 1,302 | 56,731 | - | 19.7 | 25,595 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.88 per share. | 20 Oct 2022 | 1,102 | 58,033 | - | 18.9 | 20,807 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 18.07 per share. | 20 Oct 2022 | 905 | 61,906 | - | 18.1 | 16,357 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.32 per share. | 26 Sep 2022 | 1,329 | 63,026 | - | 15.3 | 20,360 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 16.25 per share. | 26 Sep 2022 | 215 | 62,811 | - | 16.2 | 3,493 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.13 per share. | 21 Sep 2022 | 3,275 | 65,373 | - | 15.1 | 49,537 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 21 Sep 2022 | 1,018 | 64,355 | - | 15.1 | 15,341 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 15 Sep 2022 | 100 | 68,648 | - | 15.0 | 1,501 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.15 per share. | 08 Sep 2022 | 912 | 69,613 | - | 15.1 | 13,814 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 15.06 per share. | 08 Sep 2022 | 865 | 68,748 | - | 15.1 | 13,031 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 5,632 | 70,525 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 33,788 | 33,788 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 27 Jun 2022 | 7,714 | 64,893 | - | 13 | 100,282 | Common Stock |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 67,575 | 67,575 | - | - | Stock Option (Right to Buy) | |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 11,263 | 72,607 | - | 0 | Common Stock | |
| Entrada Therapeutics Inc | Nathan J. Dowden | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Oct 2021 | 95,148 | 95,148 | - | - | Stock Option (Right to Buy) |